SEC Form 4 · accession 0001731122-18-000190
Enochian Biosciences Inc · ENOB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rene Sindlev
Director · 10% Owner
Period of report
Dec 28, 2018
Accepted (ET)
Dec 28, 2018 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001527728
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 27, 2018 | P | 92,968 | $8.00 | A | 5,115,137 | I | By RS Bio ApS |
| Common Stock | Dec 27, 2018 | X | 1,307,693 | $1.30 | A | 6,422,830 | I | By RS Bio ApS |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common StockF1 | $1.30 | Dec 27, 2018 | X | 1,307,693 | D | May 15, 2017 | Apr 21, 2022 | Common Stock | 1,307,693 | 3,092,307 | I |
Explanation of responses
- F1ApS assigned its holdings in Enochian Biosciences, Inc. to RS Bio ApS. Both entities are wholly owned by Rene Sindlev.